期刊
STEM CELL REPORTS
卷 12, 期 1, 页码 29-41出版社
CELL PRESS
DOI: 10.1016/j.stemcr.2018.11.021
关键词
-
资金
- Michael J. Fox Foundation
- NIH [1RC2NS070276, 1U24NS078338-01]
- Consolidated Anti-Aging Foundation
- Orchard Foundation
- Cooper Family Fund for Parkinson's Research
- Poul Hansen Family
- National Institutes of Health [R35NS105076]
- Canada Research Chair Award [950-231859]
The Parkinson disease (PD) genetic LRRK2 gain-of-function mutations may relate to the ER pathological changes seen in PD patients at postmortem. Human induced pluripotent stem cell (iPSC)-derived neurons with the PD pathogenic LRRK2 G2019S mutation exhibited neurite collapse when challenged with the ER Ca2+ influx sarco/ER Ca2+-ATPase inhibitor thapsigargin (THP). Baseline ER Ca2+ levels measured with the ER Ca2+ indicator CEPIA-ER were lower in LRRK2 G2019S human neurons, including in differentiated midbrain dopamine neurons in vitro. After THP challenge, PD patient-derived neurons displayed increased Ca2+ influx and decreased intracellular Ca2+ buffering upon membrane depolarization. These effects were reversed following LRRK2 mutation correction by antisense oligonucleotides and gene editing. Gene expression analysis in LRRK2 G2019S neurons identified modified levels of key store-operated Ca2+ entry regulators, with no alterations in ER Ca2+ efflux. These results demonstrate PD gene mutation LRRK2 G2019S ER calcium-dependent pathogenic effects in human neurons.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据